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Background: Hepatitis B virus DNA quantification is essential for managing chronic hepa-
titis B (CHB). We compared the performance of artus HBV QS-RGQ (QIAGEN GmbH, Ger-
many) and CAP/CTM v2.0 HBV assays (Roche Molecular Diagnostics, USA) in CHB pa-
tients.
Methods: A comparative evaluation between two assays was performed with 508 clinical 
serum samples. Precision, linearity, and the limit of detection (LOD) of QS-RGQ assay was 
evaluated by using the WHO standard 97/750 and clinical samples. 
Results: Detection rates and viral loads as determined QS-RGQ assay were significantly 
lower than those from the CAP/CTM v2.0 assay (52.8% vs 60.6%; 3.55±1.77 IU/mL vs 
4.18±1.89 IU/mL, P <0.0001). The kappa coefficient between qualitative results was 0.79 
(95% confidence interval, 0.74 to 0.85). Bland-Altman plot found a mean difference of 
(QS-RGQ - CAP/CTM v2.0)=–0.63 log10 IU/mL (95% limit of agreement, –1.48 to 0.22). 
Repeatability and total imprecision (% CV) of the QS-RGQ assay were 1.0% and 1.1% at 
2,000 IU/mL, and 0.7% and 1.4% at 20,000 IU/mL, respectively. Linearity of this assay 
ranged from 31.6 to 1.0±107 IU/mL, and the LOD was 2.95 IU/mL.
Conclusions: The artus HBV QS-RGQ assay showed good performance but significantly 
decreased detection rate and viral load compared with CAP/CTM v2.0 assays. This assay 
recommends using plasma; however, we used stored serum because of the retrospective 
study design. Usually HBV DNA quantification is performed in plasma or serum, but sam-
ple type and clinical relevance of quantitative values should be considered when determin-
ing the clinical application of this reagent.
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INTRODUCTION
According to the WHO’s global estimates, more than 240 million 
people are chronically infected with Hepatitis B virus (HBV), 
and 780,000 people die every year as a consequence [1]. The 
prevalence of chronic HBV infection varies geographically, but 
Southeast Asia is an area with high prevalence (8–15%) [2]. 
Detection of HBV DNA is essential for diagnosis, and HBV DNA 
quantification is a key determinant of treatment for both HBV 
envelope antigen (HBeAg)-negative or HBeAg-positive chronic 
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Hepatitis B (CHB) [3, 4]. Recent studies suggested that after 
completing successful treatment, remaining HBV DNA corre-
lates with relapse and recurrence of HBV infection, even at a 
low concentration [5, 6].
The application of real-time PCR for viral diagnostics has been 
reported to exhibit high sensitivity, a broad dynamic range, and 
short turnaround time, and therefore is considered as the stan-
dard method for quantification [7, 8]. To date, many HBV DNA 
assays are commercially available. Although two assays may be 
comparable, assays may report discrepant viral load levels [9, 
10]. Therefore, it is important to adopt a highly reliable PCR-based 
assay to quantify HBV DNA in order to enable appropriate clini-
cal management of CHB. The QIAGEN artus HBV QS-RGQ as-
say (QIAGEN GmbH, Hilden, Germany) was newly launched but 
so far, only two abstracts have been published about its perfor-
mance [11, 12].
Our study aimed to verify the performance of the artus HBV 
QS-RGQ assay compared with the Roche COBAS AmpliPrep/
COBAS TaqMan HBV assay (Roche Molecular Diagnostics, Pleas-
anton, CA, USA) in clinical samples. 
METHODS 
1. Samples
A total of 508 serum samples where HBV DNA quantification 
had been requested by clinicians and determined by CAP/CTM 
v2.0 assay were randomly collected from 2008 to 2014. The re-
maining samples were stored at –70°C until examined by the 
artus QS-RGQ assay. This study was performed according to the 
World Medical Association’s Declaration of Helsinki guidelines 
and waived from the institutional review board of the Severance 
Hospital.
2. HBV DNA quantification assays
1) The COBAS AmpliPrep/COBAS TaqMan HBV assay (CAP/CTM v2.0)
The CAP/CTM v2.0 is an automated real-time PCR assay that 
targets the precore and core regions of the HBV genome. The 
HBV DNA preparation with the COBAS AmpliPrep instrument 
requires 650 μL of serum or plasma. DNA is extracted and eluted 
in a volume of 65 μL, 50 μL of which is then analyzed by PCR. 
Real-time PCR is performed by using the COBAS TaqMan 96 
analyzer with a multiplex TaqMan assay. Two targets are ampli-
fied, HBV DNA and the internal quantitation standard. All pro-
cedures were performed according to the manufacturer’s proto-
col. HBV DNA levels were expressed in international units per 
milliliter (IU/mL) with a conversion factor of 5.82 copies of HBV 
DNA per IU. The lower limit of detection (LOD) provided by the 
manufacturer is 20.0 IU/mL, and the dynamic range of quantifi-
cation is from 20.0 to 1.7×108 IU/mL (1.3−8.2 log10 IU/mL). This 
assay is capable of analyzing 24 specimens in about two hours 
[13-15].
2) The artus HBV QS-RGQ assay (artus QS-RGQ)
The artus QS-RGQ kit requires an input of 1,000 μL of plasma 
sample. In this study, clinical serum samples were used instead 
of plasma. Nucleic acids are extracted and eluted in a final vol-
ume of 60 μL in elution buffer. Total nucleic acids were extracted 
with the QIAsymphony SP using the QIAsymphony DSP Virus/
Pathogen Midi kits. Samples processed on the QIAsymphony 
SP can be transferred automatically to the QIAsymphony AS mod-
ule (integrated operation) for assay setup. The QIAsymphony AS 
sets up the PCR reaction by mixing 30 μL of master mix and 20 
μL of DNA template. The master mix contains reagents and en-
zymes for specific amplification of a 134-bp region of the HBV 
core gene and for direct detection of the amplicon. The real-time 
PCR was performed on Rotor-Gene Q instruments under condi-
tions described in the QIAGEN artus HBV QS-RGQ kit handbook. 
Data were analyzed with the Rotor-Gene Q software version 2.02 
using thresholds of 0.04 and 0.03 to detect signals from HBV 
and the internal control, respectively. Quantification of HBV DNA 
was determined by using 5-point external standards. The 1 IU/
mL corresponds to 8.21 copies/mL for HBV DNA detection on 
the Rotor-Gene Q. The LOD claimed by the manufacturer is 10.0 
IU/mL, and the linear range of quantification is from 31.6 to 2.0 
×107 IU/mL (1.5−7.3 log10 IU/mL) (Table 1).
Table 1. Comparison between the characteristics of two Hepatitis B 
virus (HBV) DNA quantification assays
Variables CAP/CTM v2.0 artus QS-RGQ
DNA extraction principle Magnetic particle Magnetic particle
Sample volume (μL) 650 1,200
Processed volume (μL) 500 1,000
Elution volume (μL)   65      60
Sample capacity per batch   24      24
Extraction runtime (min)* 120      90
Target HBV genome region Precore and Core Core
Claimed low limit of detection (IU/mL)    20†      10
Claimed dynamic range (IU/mL) 2.00×101 to  
1.70×108
3.16×101 to  
2.00×107
*Including the lysis step but not hands-on time; †In plasma (vs 12 IU/mL in 
serum).
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3. Interpretative criteria of HBV DNA viral load
The qualitative results were interpreted as “Detected” or “Not 
detected” on the basis of each claimed LOD. The quantitative 
results were included for further analysis, only if exceeding the 
limit of quantification (LOQ), i.e. above 20.0 IU/mL (CAP/CTM 
v2.0) and 31.6 IU/mL (artus QS-RGQ).
4. Serologic CHB assay
The HBeAg status was simultaneously evaluated by the Archi-
tect i2000SR analyzer (Abbott Diagnostics, Abbott Park, IL, USA) 
using a chemiluminescent microparticle immunoassay in clini-
cal samples before frozen storage. According to HBeAg-nega-
tive or -positive status, the differences in viral loads detected by 
the assays were determined.
5. Performance characteristics of the artus QS-RGQ assay
The second WHO international standard for HBV DNA (NIBSC 
code 97/750, 1×106 IU/mL) and clinical samples with high viral 
load were serially diluted with human serum matrix. The preci-
sion performances near the two clinically important levels (low: 
2,000 IU/mL; high: 20,000 IU/mL) were evaluated in four repli-
cates over five days using clinical samples. To evaluate linearity, 
serial dilutions of the WHO standard (20 to 105 IU/mL) and clini-
cal samples (10 to 107 IU/mL) were simultaneously tested in 
two to four replicate measurements. The diluted WHO standard 
materials of 1, 2.5, 5, 10, and 20 IU/mL were tested in 12 repli-
cates to determine the LOD.
6. Statistical analysis
Data was analyzed by using Analyse-it Method Evaluation Edi-
tion, version 3.76 software (Analyse-it Software Ltd., Leeds, UK) 
and IBM SPSS Statistics 22 (International Business Machines 
Corp., Armonk, NY, USA). The method comparisons were per-
formed by the Kappa test and Pearson Chi-squared test for quali-
tative results, and the Spearman’s test and Passing-Bablok re-
gression for quantitative results. The differences between two 
methods were presented in a Bland-Altman plot. Linear regres-
sion analysis and Probit analysis were used for verification of the 
artus QS-RGQ assay performance. The P values <0.05 were con-
sidered significant.
RESULTS 
1. Agreement and correlation between the two assays
Among the 508 serum samples tested, HBV DNA was quanti-
fied in 308 samples (60.6%) by the CAP/CTM v2.0 assay, and 
268 (52.8%) were quantified by the artus QS-RGQ assay. The 
detection rate by the artus QS-RGQ assay was significantly lower 
than that by the CAP/CTM v2.0 assay (P <0.0001). The kappa 
coefficient between the qualitative results of the two assays was 
0.79 (95% confidence interval [CI]=0.74 to 0.85). By both as-
says (Table 2), 229 (45.1%) samples were detected and 196 
(38.6%) samples were not detected. However, the CAP/CTM 
v2.0 assay detected HBV viral load in 46 (9.1%) samples wher-
eas the artus QS-RGQ did not detect HBV viral load. Conversely, 
the artus QS-RGQ assay detected six (1.2%) positive samples 
but not CAP/CTM v2.0. Overall, 12 samples with ≥20,000 IU/
mL and 29 with 2,000 to 20,000 IU/mL, based on the result 
from CAP/CTM v2.0 assay, were quantified as lower viral loads 
by the artus QS-RGQ assay. Inversely, one sample (4,230 IU/
mL) among the results from artus QS-RGQ assay was measured 
as a lower level by the CAP/CTM v2.0 assay (755 IU/mL). 
The mean±SD of HBV DNA was 4.18±1.89 IU/mL for the 
CAP/CTM v2.0 assay and 3.55±1.77 IU/mL for the artus QS-
RGQ assay. The viral loads quantified by artus QS-RGQ assay 
were significantly lower than those quantified by the CAP/CTM 
v2.0 assay (P <0.0001). Further, 38 (7.5%) samples showed 
significant difference of ≥1 log10 IU/mL. 
Both assays quantified 105 (20.7%) samples with an HBV 
DNA level <2,000 IU/mL (3.30 log10 IU/mL) and showed fair 
correlation (r=0.49; 95% CI, 0.33 to 0.63; P <0.0001). Of sam-
ples detected by both assays, Passing-Bablok regression analy-
sis and Bland-Altman plot are shown in Fig. 1A and Fig. 1B, re-
spectively.
Of the 508 study samples, 177 samples were evaluated by the 
HBeAg assay, which found 106 HBeAg-negative and 71 HBeAg-
Table 2. Comparison of viral load results in 508 clinical samples 
using the CAP/CTM v2.0 and artus QS-RGQ assays (N)
artus QS-RGQ (IU/mL)
CAP/CTM v2.0 (IU/mL)
Total
≥20,000
≥2,000 to 
<20,000
≥20 to 
<2,000
<20
≥20,000 69   0     0     0  69
≥2,000 to <20,000   9* 15     1§     0  25
≥32 to <2,000   3† 28‡ 104     4 139
<32, Detected   0   0   33     2  35
<10, Not Detected   0   1   45 196 240
Total 81 44 183 200 508
Hepatitis B virus DNA levels described below are shown as median (1st to 
3rd quartiles) (IU/mL) obtained by the artus QS-RGQ and CAP/CTM v2.0, 
respectively: *7,280 (3,324−10,500) vs 92,189 (34,467−145,000), †1,602 
(1,482−1,700) vs 41,200 (29,133−57,717), ‡812 (437−1,124) vs 6,162 
(2,752−6,848), §4,230 vs 755.
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Fig. 1. Comparison of Hepatitis B virus (HBV) DNA levels in clinical samples between CAP/CTM v2.0 and artus QS-RGQ assays (N=229). 
(A) The Passing-Bablok equation (95% CI of intercept: –0.52 to –0.27, slope: 0.92 to 0.0.96, r=0.91 to 0.95). (B) The mean difference 
(QS/RGQ-CAP/CTM) in Bland-Altman plot was –0.63±0.85 log10 IU/mL.
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Table 3. Precision performance of the artus QS-RGQ assay
Target  
   concentration  
   (log10 IU/mL)
Mean level 
(log10 IU/mL) 
SD (% CV)
Repeatability Between-day Total
3.30* 3.29 0.03 (1.0%) 0.01 (0.3%) 0.04 (1.1%)
4.30† 4.31 0.03 (0.7%) 0.05 (1.2%) 0.06 (1.4%)
*2,000 IU/ mL; †20,000 IU/mL.
Table 4. Linearity of the artus QS-RGQ assay for WHO standard and clinical samples
Assigned concentration  
   (log10 IU/mL)
WHO standard Clinical samples*
Replicates N Mean SD CV (%) Recovery % Replicates N Mean SD CV (%) Recovery %
7.00 3 6.93 0.02 0.32 98.99
6.00 3 5.95 0.01 0.10 99.14
5.00 2 4.87 0.06 1.19 97.50 3 4.98 0.03 0.50 99.52
4.00 4 4.07 0.03 0.64 101.72 2 3.93 0.03 0.87 98.27
3.00 4 3.11 0.02 0.49 103.58 2 2.93 0.03 1.10 97.61
2.00 4 2.07 0.07 3.40 103.69 2 2.06 0.25 12.17 102.97
1.30 4 1.52 0.25 16.52 116.90
1.00 2 1.15 0.49 43.02 114.88
*Concentrations measured by CAP/CTM v2.0 assay.
positive samples. The CAP/CTM assay detected 63 samples (59.4%) 
and 53 samples (74.6%), meanwhile the artus QS-RGQ assay 
detected 53 samples (50.0%) and 50 samples (70.4%) that were 
HBeAg-negative and HBeAg-positive, respectively. The tendency 
for viral load difference between the two assays was consistent 
regardless of HBeAg negativity or positivity. However, the viral 
load (mean±SD) in the HBeAg-negative group was lower than 
that in the HBeAg-positive group in both assays (3.97±0.25 vs 
5.25±0.34 for CAP/CTM assay, P <0.0001; 3.35±0.24 vs 4.60± 
0.31 for artus QS-RGQ assay, P <0.0001).
2. Performance characteristics of the artus QS-RGQ assay
The mean levels and total % CV for the artus QS-RGQ assay at 
two clinically important HBV DNA levels (target levels), i.e. 3.30 
log10 IU/mL (2,000 IU/mL) and 4.30 log10 IU/mL (20,000 IU/mL), 
were 3.29 log10 IU/mL and 4.31 log10 IU/mL, and 1.1% and 1.4%, 
respectively (Table 3). The linearity of the artus QS-RGQ assay 
was verified in the claimed linear range for each HBV DNA level 
of the WHO standard (ranged 1.30 to 5.00 log10 IU/mL, y=0.94x 
+ 0.28, r=0.995) and clinical samples (ranged 1.00 to 7.00 log10 
IU/mL, y=0.97x + 0.10, r=0.997) (Table 4). Unlike results for 
the WHO standard, the artus QS-RGQ assay showed less than 
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100% recovery at >102 IU/mL viral loads and increased % CV 
at 2.00 log10 IU/mL in clinical samples. The probit analysis for 
the artus QS-RGQ assay resulted in an LOD of 2.95 IU/mL (Ta-
ble 5).
DISCUSSION
CHB is a major cause of cirrhosis and hepatocellular carcinoma 
in Southeast Asia, China, and Africa [16]. HBV DNA quantifica-
tion is essential for monitoring disease status and treatment re-
sponse in CHB patients. Until now, several commercially avail-
able real-time PCR assays for this have been developed. Newly 
launched artus QS-RGQ assay suggested a lower LOD, higher 
sample volume, and higher LOQ than CAP/CTM v2.0 assay by 
manufacturer. This new assay has not been researched enough 
about its performance, except for two abstracts with plasma sam-
ples [11, 12]. Brichler et al [11] reported good correlation and 
agreement (r2 =0.89, mean difference=0.1 log10 IU/mL) between 
the new assay and CAP/CTM v2.0 assay. However, 23% of the 
230 samples showed more than ±0.5 log10 IU/mL difference 
range, and the HBV DNA levels by the artus QS-RGQ assay were 
lower than the results by the CAP/CTM v2.0 assay in their study 
(P value is not shown). Fielder et al [12] suggested that new as-
say showed detection capability of all eight genotypes, no cross-
reactivity with 30 different pathogens and low LOD of 4.1 IU/mL. 
In our study, there were significant differences between the 
CAP/CTM v2.0 and the artus QS-RGQ assays in the detection 
rate and viral load when quantifying HBV DNA levels in clinical 
serum samples, even though good correlation was observed (r= 
0.93). The HBV DNA levels determined by the artus QS-RGQ 
assay were substantially lower than the results by the CAP/CTM 
v2.0 assay. In addition, the correlation between the results of 
the two assays in low viral load samples (<2,000 IU/mL) was 
not as strong as the correlation for all samples (r=0.49). Accord-
ing to the manufacturer’s protocol, the LOD of the artus QS-RGQ 
assay (10 IU/mL) is lower than that of the CAP/CTM v2.0 assay 
(20 IU/mL). However, our results from the artus QS-RGQ assay 
showed a lower positive rate than those from the CAP/CTM v2.0. 
Hence, discrepancies between the assays were observed when 
sample results were plotted against important HBV DNA target 
levels for clinical management points and each claimed LOD 
and LOQ (Table 2). These discrepancies may result in different 
classifications of inactive HBsAg carriers and active CHB patients, 
and may even change CHB management strategy.
There are several possible factors that may lead to assay dis-
crepancies. Yeh et al [10] showed that the B genotype and low 
HBV viral load were two factors that contribute to significant dif-
ferences in HBV DNA viral load detection, i.e. ≥1 log10 IU/mL, 
when comparing the CAP/CTM v2.0 assay with the Real-Time 
HBV assay (Abbott Laboratories, Abbott Park, IL, USA). When 
Ismail et al [9] evaluated the Abbott RealTime HBV assay and 
artus assays on two different platforms, the two artus assays show ed 
low quantitative values in comparison with the RealTime assay, 
especially in samples with low viral load. In our study, the artus 
QS-RGQ assay also determined relatively lower viral loads than 
other assays, especially in samples with low viral load (≤2,000 
IU/mL).
Mutations in precore and core promoter regions may occur as 
CHB progresses [17]. These mutations may influence the result 
of HBV DNA quantification [18, 19]. Yeh et al [19] concluded 
that the detection difference between the CAP/CTM v2.0 and 
Abbott Real-Time assays in low viral load samples may be influ-
enced by the tyrosine-methionine-aspartate-aspartate (YMDD) 
mutation, which confers lamivudine resistance. Because of sam-
ple volume limitations, we could not genotype our samples, but 
almost all HBV genotypes are reported as genotype C in Korea, 
and mutations in the core promoter are more prevalent than mu-
tations in the precore region. Moreover, two mutations are often 
associated with HBeAg-negative results or reduced HBeAg pro-
duction [20, 21]. Thus, detection sensitivity for HBV mutants in 
the common target region may differ depending on the assay. 
However, no additional study was performed to identify HBV gen-
otype and mutation of precore and core regions due to insuffi-
cient sample volume and the retrospective study design that uti-
lized reserved samples. Finally, the artus QS-RGQ assay showed 
less reliable performance in clinical serum samples than in the 
WHO standard samples. This discrepancy may be due to the 
sample type. The QS-RGQ assay recommends the use of plasma 
samples only, while other manufacturers adopt both sample types, 
i.e. plasma or serum.
Our study has limitations because this study examined stored 
Table 5. Lower limit of detection* of the artus QS-RGQ assay
Intended concentration 
   (IU/mL)
Replicate  
N
Detected  
N
%  
Detected
Probability 
(%)
20.0 12 12 100.0 100.0
10.0 12 12 100.0 100.0
  5.0 12 12 100.0 100.0
  2.5 12 11  91.7  91.8
  1.0 12   7  58.3  58.5
*The concentration with 95% probability of detection was 2.95 IU/mL ac-
cording to probit analysis.
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clinical samples to evaluate the newly launched reagents in a 
clinical laboratory. A well-designed prospective study with freshly 
drawn blood samples is preferable according to the manufac-
turer; however, in this case, we retrospectively studied stored 
samples to determine whether to adopt a clinical test.
In conclusion, the newly launched artus QS-RGQ assay dis-
played good precision at important HBV DNA target levels, lin-
earity over clinically significant ranges, and an acceptable LOD. 
However, this assay showed a significantly decreased detection 
rate and viral load compared with results of the CAP/CTM v2.0 
assay in serum samples, especially in samples with low viral load. 
However, this assay recommends plasma only as the sample 
type. Thus, careful consideration of sample type and sample 
volume is necessary when evaluating the relevance of these re-
sults to determine the clinical application of the QS-RGQ assay.
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